Aortic stenosis (AS) and transthyretin cardiac amyloidosis (TTR-CA) are both frequent in elderly. The combination of these two diseases has never been investigated.
Background
Aortic stenosis (AS) and transthyretin cardiac amyloidosis (TTR-CA) are both frequent in elderly. The combination of these two diseases has never been investigated.
Aims
To describe patients with concomitant AS and TTR-CA.
Methods
Six cardiologic French centres identified retrospectively cases of patients with severe or moderate AS associated with TTR-CA hospitalized during the last 6 years.
Results
Sixteen patients were included. Mean + SD age was 79 + 6 years, 81% were men. Sixty per cent were NYHA III -IV, 31% had carpal tunnel syndrome, and 56% had atrial fibrillation. Median (Q1;Q4) NT-proBNP was 4382 (2425;4730) pg/mL and 91% had elevated cardiac troponin level. Eighty-eight per cent had severe AS (n ¼ 14/16), of whom 86% (n ¼ 12) had low-gradient AS. Mean + SD interventricular septum thickness was 18 + 4 mm. Mean left ventricular ejection fraction and global LS were 50 + 13% and 27 + 4%, respectively. Diagnosis of TTR-CA was histologically proven in 38%, and was based on strong cardiac uptake of the tracer at biphosphonate scintigraphy in the rest. Eighty-one per cent had wild-type TTR-CA (n ¼ 13), one had mutated Val122I and 19% did not had genetic test (n ¼ 3). Valve replacement was surgical in 63% and via transcatheter in 13%. Median follow-up in survivors was 33 (16;65) months. Mortality was of 44% (n ¼ 7) during the whole follow-up period.
Introduction
Degenerative aortic stenosis (AS) is currently the most common valvular heart disease in Western developed countries. Severe AS is defined as aortic valve area (AVA) ,1.0 cm 2 , generally with a mean gradient . 40 mmHg. Several AS patterns have been described depending on AS area, flow, gradient, and left ventricular ejection fraction (LVEF). Low-flow low-gradient AS is a severe form characterized by low cardiac output (CO), or as was defined recently by a stroke volume index (SVi),35 mL/m 2 , and low trans-valvular gradient (TG). Reduced CO could be due to decreased LVEF or to an excessive cardiac remodelling and/or restrictive physiology with preserved LVEF also called 'paradoxical low-flow low-gradient AS'. 1 Patients with this last pattern are often older and have poor prognosis. 1 Interestingly, excessive cardiac remodelling and/or a restrictive physiology are both features of another frequent disease encountered in elderly known as transthyretin (TTR) cardiac amyloidosis (TTR-CA). This disorder is characterized by extracellular deposits of fibrillar TTR proteins in different organs including the heart, resulting in LV dysfunction. 2 The two common types are wild-type transthyretin (WT-TTR) and hereditary-transthyretin (h-TTR) amyloidosis. 2 Wild-type transthyretin is also known as 'senile systemic amyloidosis' with a prevalence of 25% in the general population .80 years according to post-mortem studies. 3 Hereditary-transthyretin is inherited in an autosomal dominant mode with .120 identified mutations. 4 The penetrance and severity of the disease are variable and depend on the mutation with some associated almost exclusively with cardiac involvement (e.g. Val122Ile). Transthyretin cardiac amyloidosis (TTR-CA) patients usually have biventricular increased wall thicknesses, diffuse late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (MRI) and cardiac uptake at biphosphonate scintigraphy (BS).
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Transthyretin cardiac amyloidosis carries poor prognosis and is often complicated by HF. Although aging associated factors may influence the development or progression of AS, the combination AS and TTR-CA remains poorly described.
The aims of this study were to report cases of patients with both TTR-CA and AS in order to describe their specific phenotype, management, and outcomes.
Methods
Six centres had to identify in their records patients with AS and TTR-CA for the last 6 years. Inclusion criteria were diagnosis of CA associated with a moderate or severe aortic valve stenosis (aortic valve area ,1.5 cm 2 ). Diagnosis of TTR-CA had to be confirmed on endomyocardial biopsy or by strong cardiac retention (visual score ≥ 2) at BS ( 99m Tc-HMDP or 99m
Tc-DPD). Patients were managed according to contemporary guidelines. 6 The investigation was in line with the Declaration of Helsinki.
Clinical, biological, trans-thoracic echocardiography (TTE), cardiac MRI, BS, histology, and treatment data were recorded.
Outcomes and follow-up
Follow-up began at the time of decision for AS management and was based on medical examination or telephone interviews.
Statistical analysis
Continuous variables were described as mean + SD or median (25th;75th inter-quartile range) and dichotomous as percentage. Statistical analyses were performed using SPSS software.
Results
Clinical and biological characteristics of patients with aortic stenosis/transthyretin cardiac amyloidosis combination
Sixteen patients with the combination of AS and TTR-CA were analysed ( Table 1 ). All of them were referred for AS management or for persistent dyspnoea after surgical AVR with an associated diagnosis of CA.
The mean age was 79 + 6 years, 81% were men (n ¼ 13), 60% (n ¼ 9/14) were in NYHA-class III or IV. Carpal tunnel syndrome was observed in 31% of the patients (n ¼ 5/16), atrial fibrillation in 56% (n ¼ 9/16). The patients had also elevated levels of biomarkers of HF with a median of NT-proBNP of 4382(2425;4730) pg/mL. Troponin was elevated in 10 of the 11 patients with available data.
Before AS management, 88% (n ¼ 14) had severe AS of whom 86% (n ¼ 12/14) had low transaortic gradient and 87% had low-flow AS defined by SVi , 35 ml/m 2 (n ¼ 13/15). They all had increased interventricular septum thickness (18 + 4 mm). Left ventricular dysfunction was moderate when estimated by LVEF (50 + 13%). However, when it was available, global LS was dramatically decreased (27 + 4%).
Diagnosis of transthyretin cardiac amyloidosis
Eighty-one per cent (n ¼ 13) had WT-TTR and one h-TTR with Val122I mutation. Three did not have genetic sequencing of TTR.
The diagnosis of TTR-CA was histologically proved in 6 (38%) and on scintigraphy for the other patients. Seventy-five per cent of the patients (n ¼ 12) had cardiac MRI with all showing diffuse LGE.
Management of aortic stenosis/ transthyretin cardiac amyloidosis patients and outcomes
Based on Heart-Team decision, 10 patients (63%) were referred for aortic valve replacement (AVR), of whom one refused surgery; transcatheter aortic valve implantation (TAVI) was scheduled in two cases (12%), of whom one died before the procedure. Conservative treatment was indicated in four patients (25%). The follow-up for the survivors was 33 (16;65) months. Forty-four (n ¼ 7) died during follow-up, four from HF, one from pneumopathy, one of cardiogenic shock (before undergoing TAVI), and one at home from unknown cause. There were no significant differences in baseline characteristics between the alive and the dead groups ( Table 2 ). Figure 1 shows an example of a patient with the combination of AS and TTR-CA treated by TAVI.
Discussion
To the best of our knowledge, our study provides for the first time a clinical description of the combination of AS and TTR-CA. This study suggests that TTR-CA should be suspected in elderly patients with severe AS and low-flow low gradients, especially in the presence of carpal tunnel syndrome, excessive cardiac 'hypertrophic remodelling', and signs of HF.
Diagnosing cardiac amyloidosis in aortic stenosis
In elderly patients with AS, CA should be suspected in presence of carpal tunnel syndrome, severe dyspnoea (NYHA III -IV), markedly increase of NT-proBNP or troponins and/or TTE with altered LV-LS and/or diffuse cardiac MRI-LGE. In this population, with advanced age, non-invasive tools such as, BS should be performed to screen TTR-CA. If the BS shows cardiac fixation, TTR-CA diagnosis needs then to be confirmed by biopsy (extracardiac/cardiac) and a TTR genetic testing should be done. Recognition of TTR-CA is crucial, as several specific therapeutic trials are in progress.
Aortic stenosis and transthyretin cardiac amyloidosis: more than a simple epiphenomenon
It is unclear if there is a causative link between AS and TTR-CA. Both are observed in the elderly and the one may argue that their association is due to chance. There is increasing data in the literature supporting a central role of oxidative stress, inflammation, and extracellular remodelling in the TTR amyloidogenic process. 2, 7 These mechanisms are also part of the pathophysiology of AS. 8, 9 It is conceivable that amyloid deposits could be induced or accelerated in AS. Interestingly, similar echocardiographic features are seen in CA and AS: CA is known to induce basal LS abnormalities with a relative apical sparing related to amyloid deposits. 10 Similar abnormalities have been observed in severe AS and were attributed mainly to myocardial fibrosis. 11 It may be possible that basal LS impairment in some patients with AS is, in fact, due to amyloid infiltration. This is supported by Allen et al. who found a prevalence of 10% of TTR amyloid deposits on septal myectomy during surgical AVR for AS.
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Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?
The question of whether CA is a cause or a consequence of AS is unknown. On one hand, the amyloid deposits could induce or worsen AS as shown by Kristen et al. who reported a high prevalence of amyloid deposits in surgically removed heart valves, mainly in AS (74% of aortic valves); 13 on the other hand, pressure overload produced by AS could have deleterious effects on myocardial remodelling and so may induce or worsen TTR amyloid deposits. We report here few cases identified retrospectively. Only severe cases or unusual presentation of AS were suspected and investigated for CA. Thus, the association of these two diseases might be more frequent than thought. An ongoing prospective and consecutive multicenter study was designed to determine the prevalence of TTR-CA in AS (NCT02260466).
Consequences of Aortic stenosis/ transthyretin cardiac amyloidosis combination on clinical management
Management of AS and TTR-CA patients is challenging. Once diagnosed, b-blockers should be avoided and pacemaker implant discussed depending on conduction disorder. Aortic valve replacement option needs to be discussed individually as it is too early to define the best strategy. Improvement after AVR might be limited in terms of survival and symptoms. Furthermore, these patients are at high risk of having operative and post-operative complications. 14, 15 Transcatheter aortic valve implantation which is generally indicated for high-risk patients may not be optimal in this particular population with risk of left ventricular rupture and complete atrioventricular block leading both to death in per or post-TAVI procedure. 16, 17 Moreover, autopsy data in patients who had previously undergone TAVI revealed myocardial amyloid deposits in nearly one-third of examined cases, which may contribute to poor outcomes. 18 Thus, diagnosis workup of TTR-CA should be performed before referring a patient with suspected TTR-CA for surgical AVR or TAVI in severe AS.
Limitations
There are several limitations. First, this is a retrospective study. Thus, it is not possible to calculate the prevalence of TTR-CA in AS. Furthermore, we can suppose that the diagnosis of TTR-CA was made in this specific group of AS patients because they were referred initially to surgery with a suggestive phenotype of TTR-CA, i.e. important increase in LV wall thickness, altered LV-LS, increased NT-proBNP, and persistent dyspnoea after AVR. Cardiac biopsy was not possible to obtain from all the patients, thus scintigraphy was used to make the diagnosis. All patients had visual score . 2 at hydroxy methylene diphosphonate (HMDP) scintigrpahy which as we have reported is 100% specific. 19 It is to note that amyloid deposits could be focal, thus a negative cardiac biopsy could not exclude amyloidosis. Nevertheless, this study brings some insights of the clinical feature of TTR-CA in AS. Our prospective study (NCT02260466) is aimed at determining the prevalence, phenotype, and outcomes of TTR-CA in AS.
Conclusion
Patients with AS and TTR-CA have specific features, i.e. age ≥ 70 years, male gender, carpal tunnel syndrome, severe dyspnoea, low-flow AS, and excessive 'hypertrophic remodelling'. Patients with suspicion of this association should be screened for CA and managed accordingly. Values are n (percentage) or median (Q1;Q4). CT, carpal tunnel syndrome; AF, atrial fibrillation; ASA, aortic surface area; MG, mean gradient; CO, cardiac output; SVi, indexed stroke volume; LVEF, left ventricular ejection fraction; GLS, global longitudinal strain; IVST, interventricular septum thickness; BS, cardiac uptake at bone scintigraphy; Surgery, surgical aortic valve replacement; TAVI, trans-aortic valve implantation. Proportions were compared using x 2 test or the Fisher's exact test when the number of patients was less than five in a group. a Only two patients had data available in the dead group. Only including the 15 patients with severe aortic stenosis; only 10 of 13 patients with bone scintigraphy had visual score estimated.
